

Jose M Garcia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4428400/publications.pdf>

Version: 2024-02-01

56
papers

3,342
citations

218677

26
h-index

155660

55
g-index

58
all docs

58
docs citations

58
times ranked

4647
citing authors

#	ARTICLE	IF	CITATIONS
1	Androgens and estrogens predict sexual function after autologous hematopoietic stem cell transplant in men. <i>Andrology</i> , 2022, 10, 291-302.	3.5	3
2	Appendicular Lean Mass, Grip Strength, and the Development of Hospital-Associated Activities of Daily Living Disability Among Older Adults in the Health ABC Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 1398-1404.	3.6	7
3	Whole-body and adipose tissue metabolic phenotype in cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1124-1133.	7.3	17
4	Evaluation of physical function and its association with body composition, quality of life and biomarkers in cancer cachexia patients. <i>Clinical Nutrition</i> , 2021, 40, 978-986.	5.0	16
5	Experience of a Pituitary Clinic for US Military Veterans With Traumatic Brain Injury. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab005.	0.2	5
6	A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture. <i>Scientific Reports</i> , 2021, 11, 4609.	3.3	14
7	Growth hormone secretagogue receptor-1a mediates ghrelin's effects on attenuating tumour-induced loss of muscle strength but not muscle mass. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1280-1295.	7.3	8
8	Gout and open-angle glaucoma risk in a veteran population. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 3371-3379.	1.9	2
9	Muscle mass, not radiodensity, predicts physical function in cancer patients with or without cachexia. <i>Oncotarget</i> , 2020, 11, 1911-1921.	1.8	6
10	Ghrelin ameliorates tumor-induced adipose tissue atrophy and inflammation <i>via</i> Ghrelin receptor-dependent and -independent pathways. <i>Oncotarget</i> , 2020, 11, 3286-3302.	1.8	14
11	Editorial: Neuroendocrine Disorders After Traumatic Brain Injury: Past, Present and Future. <i>Frontiers in Endocrinology</i> , 2019, 10, 386.	3.5	7
12	Assessing Cachexia Acutely after Autologous Stem Cell Transplant. <i>Cancers</i> , 2019, 11, 1300.	3.7	11
13	Cancer-driven changes link T cell frequency to muscle strength in people with cancer: a pilot study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 827-843.	7.3	15
14	Clinical research in older adults with hematologic malignancies: Opportunities for alignment in the Veterans Affairs. <i>Seminars in Oncology</i> , 2019, 46, 341-345.	2.2	0
15	Management of Opioid-Induced Constipation in Patients with Malignancy. <i>American Journal of Medicine</i> , 2018, 131, 1041-1051.e3.	1.5	3
16	The habenula as a novel link between the homeostatic and hedonic pathways in cancer-associated weight loss: a pilot study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 497-504.	7.3	12
17	Cannabinoids in Patients with Nausea and Vomiting Associated with Malignancy and Its Treatments. <i>American Journal of Medicine</i> , 2018, 131, 755-759.e2.	1.5	6
18	Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects. <i>Molecular and Cellular Endocrinology</i> , 2018, 464, 65-74.	3.2	49

#	ARTICLE	IF	CITATIONS
19	Ghrelin deletion protects against age-associated hepatic steatosis by downregulating the C/EBP β -p300/DGAT1 pathway. <i>Aging Cell</i> , 2018, 17, e12688.	6.7	32
20	Off-Label Megestrol in Patients with Anorexia-Cachexia Syndrome Associated with Malignancy and Its Treatments. <i>American Journal of Medicine</i> , 2018, 131, 623-629.e1.	1.5	5
21	Elimination of Age-Associated Hepatic Steatosis and Correction of Aging Phenotype by Inhibition of cdk4-C/EBP β -p300 Axis. <i>Cell Reports</i> , 2018, 24, 1597-1609.	6.4	35
22	Macimorelin as a Diagnostic Test for Adult GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3083-3093.	3.6	71
23	Update on Management of Cancer-Related Cachexia. <i>Current Oncology Reports</i> , 2017, 19, 3.	4.0	43
24	Nonsteroidal Anti-Inflammatory Drugs in Patients with Anorexia-Cachexia Syndrome Associated with Malignancy and Its Treatments. <i>American Journal of Medicine</i> , 2017, 130, 1033-1036.	1.5	2
25	Deletion of ghrelin prevents aging-associated obesity and muscle dysfunction without affecting longevity. <i>Aging Cell</i> , 2017, 16, 859-869.	6.7	26
26	Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. <i>Scientific Reports</i> , 2017, 7, 2273.	3.3	69
27	Omega-3 Fatty Acids in Patients with Anorexia-Cachexia Syndrome Associated with Malignancy and Its Treatments. <i>American Journal of Medicine</i> , 2017, 130, 1151-1155.	1.5	4
28	What is next after anamorelin?. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 266-271.	1.3	16
29	Sex Differences in Muscle Wasting. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1043, 153-197.	1.6	145
30	The Small Molecule Nobiletin Targets the Molecular Oscillator to Enhance Circadian Rhythms and Protect against Metabolic Syndrome. <i>Cell Metabolism</i> , 2016, 23, 610-621.	16.2	380
31	Preoperative cancer cachexia and short-term outcomes following surgery. <i>Journal of Surgical Research</i> , 2016, 205, 398-406.	1.6	22
32	Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review. <i>Endocrine-Related Cancer</i> , 2016, 23, R393-R409.	3.1	43
33	Evaluation of Veterans MOVE! Program for Weight Loss. <i>Journal of Nutrition Education and Behavior</i> , 2016, 48, 299-303.e1.	0.7	14
34	Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015, 6, 132-143.	7.3	165
35	Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. <i>Lancet Oncology</i> , The, 2015, 16, 108-116.	10.7	176
36	Ghrelin Partially Protects Against Cisplatin-Induced Male Murine Gonadal Toxicity in a GHSR-1a-Dependent Manner. <i>Biology of Reproduction</i> , 2015, 92, 76.	2.7	26

#	ARTICLE	IF	CITATIONS
37	Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opinion on Pharmacotherapy, 2015, 16, 1245-1253.	1.8	45
38	Ghrelin Prevents Cisplatin-Induced Testicular Damage by Facilitating Repair of DNA Double Strand Breaks Through Activation of p53 in Mice. Biology of Reproduction, 2015, 93, 24.	2.7	25
39	Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options - A Mini-Review. Gerontology, 2014, 60, 294-305.	2.8	338
40	Circulating Inflammatory Cytokines and Adipokines Are Associated With Increased Risk of Barrett's Esophagus: A Case-Control Study. Clinical Gastroenterology and Hepatology, 2014, 12, 229-238.e3.	4.4	71
41	A Multibiomarker Risk Score Helps Predict Risk for Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2014, 12, 1267-1271.	4.4	66
42	Reversible Adrenal Insufficiency in Three Patients With Post-Roux-en-Y Gastric Bypass Noninsulinoma Pancreatogenous Hypoglycemia Syndrome. Journal of Investigative Medicine High Impact Case Reports, 2014, 2, 232470961452699.	0.6	1
43	Inhibition of Cisplatin-Induced Lipid Catabolism and Weight Loss by Ghrelin in Male Mice. Endocrinology, 2013, 154, 3118-3129.	2.8	87
44	Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Supportive Care in Cancer, 2013, 21, 129-137.	2.2	141
45	Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment. Current Opinion in Supportive and Palliative Care, 2013, 7, 368-375.	1.3	27
46	Low Testosterone Levels and Increased Inflammatory Markers in Patients with Cancer and Relationship with Cachexia. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E700-E709.	3.6	91
47	Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 245-251.	7.3	77
48	Testosterone replacement for fatigue in male hypogonadic patients with advanced cancer: A preliminary double-blind placebo-controlled trial. Journal of Clinical Oncology, 2012, 30, e19643-e19643.	1.6	0
49	Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Hormone and IGF Research, 2009, 19, 267-273.	1.1	76
50	Characterization of Adult Ghrelin and Ghrelin Receptor Knockout Mice under Positive and Negative Energy Balance. Endocrinology, 2008, 149, 843-850.	2.8	235
51	Ghrelin Prevents Cisplatin-Induced Mechanical Hyperalgesia and Cachexia. Endocrinology, 2008, 149, 455-460.	2.8	112
52	Effect on Body Weight and Safety of RC1291, a Novel, Orally Available Ghrelin Mimetic and Growth Hormone Secretagogue: Results of a Phase I, Randomized, Placebo-Controlled, Multiple-Dose Study in Healthy Volunteers. Oncologist, 2007, 12, 594-600.	3.7	115
53	Rise of Plasma Ghrelin With Weight Loss is Not Sustained During Weight Maintenance. Obesity, 2006, 14, 1716-1723.	3.0	54
54	Hypogonadism in male patients with cancer. Cancer, 2006, 106, 2583-2591.	4.1	88

#	ARTICLE	IF	CITATIONS
55	Active Ghrelin Levels and Active to Total Ghrelin Ratio in Cancer-Induced Cachexia. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2920-2926.	3.6	222
56	High-Dose Benzodiazepine Therapy in Hospitalized Anxious Patients. Journal of Clinical Pharmacology, 1983, 23, 100-105.	2.0	1